Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection

Current Opinion in Microbiology

Volumn 16, Issue 5, 2013, Pages 596-601

  Adamu, Blessing O ^a   Lawley, Trevor D ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIARRHEA; ENTEROPATHY; EXPERIMENTAL STUDY; FECES MICROFLORA; FERMENTATION; HUMAN; INTESTINAL DYSBIOSIS; INTESTINE FLORA; LACHNOSPIRACEAE; NONHUMAN; PATHOGENESIS; PATIENT SAFETY; RECURRENT INFECTION; REVIEW; RUMINOCOCCACEAE; SALMONELLA TYPHIMURIUM; TOXIC MEGACOLON;

CLOSTRIDIUM DIFFICILE;

BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DYSBIOSIS; ENTERITIS; HUMANS;

EID: 84887625620     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.06.009     Document Type: Review

References (54)

1. Morgan X.C., Segata N., Huttenhower C. Biodiversity and functional genomics in the human microbiome. Trends Genet 2012, 29:51-58.
2. Lawley T.D., Walker A.W. Intestinal colonization resistance. Immunology 2013, 138:1-11.
3. He M., Miyajima F., Roberts P., Ellison L., Pickard D.J., Martin M.J., Connor T.R., Harris S.R., Fairley D., Bamford K.B., D'Arc S., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45:109-113.
4. Freeman J., Bauer M.P., Baines S.D., Corver J., Fawley W.N., Goorhuis B., Kuijper E.J., Wilcox M.H. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-549.
5. Clements A.C.A., Magalhes R.J.S., Tatem A.J., Paterson D.L., Riley T.V. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010, 10:395-404.
6. Borody T.J., Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 2012, 9:88-96.
7. Sekirov I., Russell S.L., Antunes L.C.M., Finlay B.B. Gut microbiota in health and disease. Physiol Rev 2010, 90:859-904.
8. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., Mende D.R., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
9. Fraher M.H., O'Toole P.W., Quigley E.M.M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012, 9:312-322.
10. Dave M., Higgins P.D., Middha S., Rioux K.P. The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 2012, 160:246-257.
11. Maurice C.F., Haiser H.J., Turnbaugh P.J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013, 152:39-50.
12. Kau A.L., Ahern P.P., Griffin N.W., Goodman A.L., Gordon J.I. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
13. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
14. Jernberg C., Löfmark S., Edlund C., Jansson J.K. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010, 156:3216-3223.
15. Manichanh C., Borruel N., Casellas F., Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012, 9:599-608.
16. Azad M.B., Kozyrskyj A.L. Perinatal programming of asthma: the role of gut microbiota. Clin Dev Immunol 2012, 2012:9.
17. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., Sogin M.L., Jones W.J., Roe B.A., Affourtit J.P., Egholm M., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
18. Stecher B., Robbiani R., Walker A.W., Westendorf A.M., Barthel M., Kremer M., Chaffron S., Macpherson A.J., Buer J., Parkhill J., Dougan G., et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol 2007, 5:2177-2189.
19. Lupp C., Robertson M.L., Wickham M.E., Sekirov I., Champion O.L., Gaynor E.C., Finlay B.B. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae. Cell Host Microbe 2007, 2:119-129.
20. Dethlefsen L., Relman D.A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011, 108:4554-4561.
21. Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M., Young V.B. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008, 197:435-438.
22. Binder H.J. Role of colonic short-chain fatty acid transport in diarrhea. Annu Rev Physiol 2010, 72:297-313.
23. Robinson C.J., Young V.B. Antibiotic administration alters the community structure of the gastrointestinal microbiota. Gut Microbes 2010, 1:279-284.
24. Rea M.C., Dobson A., O'Sullivan O., Crispie F., Fouhy F., Cotter P.D., Shanahan F., Kiely B., Hill C., Ross R.P. Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2011, 108:4639-4644.
25. Ubeda C., Taur Y., Jenq R.R., Equinda M.J., Son T., Samstein M., Viale A., Socci N.D., van den Brink M.R.M., Kamboj M., Pamer E.G. Vancomycin-resistant enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Investig 2010, 120:4332-4341.
26. Louie T.J., Miller M.A., Mullane K.M., Weiss K., Lentnek A., Golan Y., Gorbach S., Sears P., Shue Y.K. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
27. Lode H.M. Clinical impact of antibiotic-resistant gram-positive pathogens. Clin Microbiol Infect 2009, 15:212-217.
28. Cochetière M.F., Durand T., Lalande V., Petit J.C., Potel G., Beaugerie L. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol 2008, 56:395-402.
29. Deakin L.J., Clare S., Fagan R.P., Dawson L.F., Pickard D.J., West M.R., Wren B.W., Fairweather N.F., Dougan G., Lawley T.D. The Clostridium difficile spo0A gene is a persistence and transmission factor. Infect Immun 2012, 80:2704-2711.
30. Ghantoji S.S., Sail K., Lairson D.R., DuPont H.L., Garey K.W. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010, 74:309-318.
31. Carter G.P., Rood J.I., Lyras D. The role of toxin a and toxin b in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 2010, 1:58-64.
32. Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A., Kelly C., Khoruts A., Louie T., Martinelli L.P., Moore T.A., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9:1044-1049.
33. Underwood S., Guan S., Vijayasubhash V., Baines S.D., Graham L., Lewis R.J., Wilcox M.H., Stephenson K. Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol 2009, 191:7296-7305.
34. Rea M.C., O'Sullivan O., Shanahan F., O'Toole P.W., Stanton C., Ross R.P., Hill C. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 2012, 50:867-875.
35. Cornely O.A., Crook D.W., Esposito R., Poirier A., Somero M.S., Weiss K., Sears P., Gorbach S. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012, 12:281-289.
36. van Nood E., Speelman P., Kuijper E.J., Keller J.J. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution?. Euro Surveill 2009, 14:19316.
37. Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010, 44:354-360.
38. Rubin T.A., Gessert C.E., Aas J., Bakken J.S. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 2013, 19:22-26.
39. Bakken J.S. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009, 15:285-289.
40. Shahinas D., Silverman M., Sittler T., Chiu C., Kim P., Allen-Vercoe E., Weese S., Wong A., Low D.E., Pillai D.R. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. mBio 2012, 3.
41. Hamilton M.J., Weingarden A.R., Unno T., Khoruts A., Sadowsky M.J. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013, 4:125-135.
42. Yoon S.S., Brandt L.J. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010, 44:562-566.
43. van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M., Visser C.E., Kuijper E.J., Bartelsman J.F.W.M., Tijssen J.G.P., Speelman P., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013, 368:407-415.
44. Zipursky J.S., Sidorsky T.I., Freedman C.A., Sidorsky M.N., Kirkland K.B. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012, 55:1652-1658.
45. Tvede M., Rask-Madsen J. Bactheriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 333:1156-1160.
46. Petrof E., Gloor G., Vanner S., Weese S., Carter D., Daigneault M., Brown E., Schroeter K., Allen-Vercoe E. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1:3.
47. Relman D.A. Restoration of the gut microbial habitat as a disease therapy. Nat Biotechnol 2013, 31:35-37.
48. Lawley T.D., Clare S., Walker A.W., Stares M.D., Connor T.R., Raisen C., Goulding D., Rad R., Schreiber F., Brandt C., Deakin L.J., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 2012, 8:e1002995.
49. Reeves A.E., Koenigsknecht M.J., Bergin I.L., Young V.B. Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family lachnospiraceae. Infect Immun 2012, 80:3786-3794.
50. Goodman A.L., Kallstrom G., Faith J.J., Reyes A., Moore A., Dantas G., Gordon J.I. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc Natl Acad Sci U S A 2011, 108:6252-6257.
51. Borody T.J., Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin N Am 2012, 41:781-803.
52. Duplessis C.A., You D., Johnson M., Speziale A. Efficacious outcome employing fecal bacteriotherapy in severe Crohn's colitis complicated by refractory Clostridium difficile infection. Infection 2012, 40:469-472.
53. Schwiertz A., Taras D., Schäfer K., Beijer S., Bos N.A., Donus C., Hardt P.D. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010, 18:190-195.
54. Vrieze A., Van Nood E., Holleman F., Salojärvi J., Kootte R.S., Bartelsman J.F.W.M., Dallinga-Thie G.M., Ackermans M.T., Serlie M.J., Oozeer R., Derrien M., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143. 913.e7-916.e7.